Soleus Capital Management’s Mirum Pharmaceuticals MIRM Stock Holding History

Soleus Capital Management’s Portfolio MIRM Stock Details MIRM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$8.78M	Sell	75,000 -325,306	-81%	-$32.7M	0.3%	61
2026 Q1	$37M	Sell	400,306 -173,308	-30%	-$16.3M	1.5%	21
2025 Q4	$45.3M	Buy	573,614 +424,918	+286%	+$30.5M	1.67%	15
2025 Q3	$10.9M	Sell	148,696 -150,000	-50%	-$9.54M	0.55%	43
2025 Q2	$15.2M	Buy	+298,696	New	+$13.3M	1.01%	29
2023 Q4	–	Sell	-103,000	Closed	-$3.25M	–	95
2023 Q3	$3.25M	Sell	103,000 -73,000	-41%	-$2M	0.3%	61
2023 Q2	$4.55M	Sell	176,000 -66,000	-27%	-$1.76M	0.51%	50
2023 Q1	$5.81M	Buy	+242,000	New	+$5.52M	0.6%	48
2022 Q4	–	Sell	-135,618	Closed	-$2.85M	–	83
2022 Q3	$2.85M	Sell	135,618 -60,400	-31%	-$1.45M	0.39%	54
2022 Q2	$3.81M	Sell	196,018 -147,482	-43%	-$3.48M	0.6%	49
2022 Q1	$7.56M	Buy	+343,500	New	+$7.01M	0.98%	34

Other funds holding MIRM

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

Jupiter Topco New York $245B AUM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $33.3B AUM 44.76% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Soleus Capital Management's MIRM Position: Q2 2026 in Review

Soleus Capital Management reduced its Mirum Pharmaceuticals (MIRM) stake by 81% in Q2 2026, selling an estimated $32.7M and leaving 75,000 shares worth $8.78M. The position accounts for 0.3% of the portfolio, ranked #61.

Soleus Capital Management first reported a position in MIRM in Q1 2022 and has held it in 11 quarters since. The position peaked at $45.3M in Q4 2025. 327 funds tracked by Wall St. Rank hold MIRM as of Q2 2026.

Soleus Capital Management held 75,000 shares of Mirum Pharmaceuticals worth $8.78M as of Q2 2026.
Soleus Capital Management sold 325,306 Mirum Pharmaceuticals shares in Q2 2026, an estimated $32.7M.
Mirum Pharmaceuticals made up 0.3% of Soleus Capital Management's portfolio in Q2 2026, its #61 holding.
Soleus Capital Management first reported a position in Mirum Pharmaceuticals in Q1 2022 and has held it in 11 quarters since.
Soleus Capital Management's Mirum Pharmaceuticals position peaked at $45.3M in Q4 2025.
327 funds tracked by Wall St. Rank held Mirum Pharmaceuticals as of Q2 2026.

Based on Soleus Capital Management's 13F filing for Q2 2026, filed 11 Aug 2026.